Our laboratory pioneered the di-2-pyridylketone thiosemicarbazone class of ligands (DpT; Fig. 1) that show pronounced and selective anti-tumor activity against a variety of cancers in vivo and demonstrate the ability to overcome drug resistance via a number of mechanisms.13–19 This marked and safe anti-tumor activity was confirmed by multiple other groups in vitro and in vivo. This evidence concerns the gene DPT and neoplasm.